Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1562-1568

  Chen, Jie ^a,b   Su, Changqing ^a,b   Lu, Qiujun ^e   Shi, Wenfang ^a,b   Zhang, Qi ^a,b   Wang, Xinghua ^a,b   Long, Ju ^d   Yang, Qin ^d   Li, Nfang ^a,b   Jia, Xiaoyuan ^c   Wang, Jianming ^a,b   Da, Wanming ^f   Liu, Xinyuan ^c,d   Wu, Mengchao ^a,b   Qian, Qijun ^a,d,g  

^a Laboratory of Viral and Gene Therapy   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^d ZHEJIANG SCI TECH UNIVERSITY   (China)

^e BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD20 ANTIBODY; RITUXIMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; MALE; MONKEY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAJI CELL; TUMOR XENOGRAFT; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; GENETICS; IMMUNOLOGY; MACACA; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL LINE, TUMOR; HUMANS; LYMPHOCYTE DEPLETION; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C;

EID: 49849096791     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0297     Document Type: Article

References (43)

1. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51.
2. Carter RH. B cells in health and disease. Mayo Clin Proc 2006;81:377-84.
3. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004;4:398-402.
4. Hatake K, Mishima Y, Terui Y. Rituximab and hematological malignancy. Nippon Rinsho 2004;62:1321-4.
5. Mariette X. Treatment of oral dryness in Sjogren's syndrome. Rev Med Interne 2004;25:287-93.
6. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-7.
7. Silverman GJ. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci 2007;12:2194-206.
8. El-Habbash MM, Alwindi AM. Progress in immunotherapy rituximab. Saudi Med J 2007;28:1635-44.
9. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006;5:18-24.
10. Tanaka Y. Anti-CD20 antibody therapy for inflammatory immune diseases. Nippon Naika Gakkai Zasshi 2006;95:1801-6.
11. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
12. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74.
13. Fang J, Qian JJ, Yi S, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005;23:584-90.
14. Noel D, Pelegrin M, Marin M, et al. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum Gene Ther 1997;8:1219-29.
15. Pelegrin M, Marin M, Noel D, Piechaczyk M. Genetically engineered antibodies in gene transfer and gene therapy. Hum Gene Ther 1998;9:2165-75.
16. Marin M, Pelegrin-Zurilla M, Bachrach E, Noel D, Brockly F, Piechaczyk M. Antiviral activity of an intracellularly expressed single-chain antibody fragment directed against the murine leukemia virus capsid protein. Hum Gene Ther 2000;11:389-401.
17. Guo MG, Jiang MH, Yang Q, et al. Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene. Zhonghua Yi Xue Za Zhi 2004;84:1147-51.
18. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43.
19. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288:371-8.
20. Armbruster C, Stiegler GM, Vcelar BA, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002;16:227-33.
21. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004;6 Suppl 1:S164-171.
22. Zhang S, Xu G, Liu C, et al. Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int J Hyperthermia 2005;21:631-6.
23. Franceschi RT. Biological approaches to bone regeneration by gene therapy. J Dent Res 2005;84:1093-103.
24. Kawabata K, Sakurai F, Yamaguchi T, Hayakawa T, Mizuguchi H. Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. Mol Ther 2005;12:547-54.
25. Kumahara K, Nagata H, Watanabe K, et al. Suppression of inflammation by dexamethasone prolongs adenoviral vector-mediated transgene expression in murine nasal mucosa. Acta Otolaryngol 2005;125:1301-6.
26. Wang AY, Peng PD, Ehrhardt A, Storm TA, Kay MA. Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum Gene Ther 2004;15:405-13.
27. Imperiale MJ, Kochanek S. Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol 2004;273:335-57.
28. Sakurai F, Mizuguchi H, Yamaguchi T, Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 2003;8:813-21.
29. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol 1995;199:237-74.
30. Noel D, Pelegrin M, Kramer S, Jacquet C, Skander N, Piechaczyk M. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther 2002;13:1483-93.
31. Zhang Q, Nie M, Sham J, et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 2004;64:5390-7.
32. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003;12:19-28.
33. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
34. Marasco WA. Therapeutic antibody gene transfer. Nat Biotechnol 2005;23:551-2.
35. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.
36. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000;204:55-63.
37. Noel D, Pelegrin M, Brockly F, Lund AH, Piechaczyk M. Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts. J Invest Dermatol 2000;115:740-5.
38. Perez N, Bigey P, Scherman D, Danos O, Piechaczyk M, Pelegrin M. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther 2004;2:2.
39. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. J Infect Dis 1995;171:1090-6.
40. Schulick AH, Vassalli G, Dunn PF, et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 1997;99:209-19.
41. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996;3:137-44.
42. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003;10:955-63.
43. Herzog RW. Recent advances in hepatic gene transfer: more efficacy and less immunogenicity. Curr Opin Drug Discov Devel 2005;8:199-206.